Trending Stock News

Researchers at Peel Hunt Reiterated their Buy rating for Euromoney Institutional Investor PLC (LON:ERM). The Target Price per Share is Set to GBX 1330.00; Torray Has Lowered By $11.18 Million Its Gilead Sciences (GILD) Holding

Peel Hunt have a GBX 1330.00 TP on the stock. The TP would indicate a potential upside of 18.22% from Euromoney Institutional Investor PLC (LON:ERM)‘s current price. This rating was shown in analysts report on Monday morning.

Torray Llc decreased Gilead Sciences (GILD) stake by 95.6% reported in 2017Q2 SEC filing. Torray Llc sold 159,692 shares as Gilead Sciences (GILD)’s stock declined 8.05%. The Torray Llc holds 7,358 shares with $521,000 value, down from 167,050 last quarter. Gilead Sciences now has $98.41 billion valuation. The stock increased 0.75% or $0.56 during the last trading session, reaching $75.34. About 8.43 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since December 4, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

The stock decreased 0.53% or GBX 6 during the last trading session, reaching GBX 1125. About 769 shares traded. Euromoney Institutional Investor PLC (LON:ERM) has 0.00% since December 4, 2016 and is . It has underperformed by 16.70% the S&P500.

Euromoney Institutional Investor PLC, together with its subsidiaries, operates as a business-to-business information firm in the United Kingdom, North America, and internationally. The company has market cap of 1.21 billion GBP. It operates through four divisions: Asset Management; Pricing, Data and Market Intelligence; Banking and Finance; and Commodity Events. It has a 50.68 P/E ratio. The companyÂ’s Asset Management segment offers independent research, news, and data services for investors under BCA and Ned Davis Research brand names, as well as operates networks and conferences that bring asset allocators and asset managers together.

Among 7 analysts covering Euromoney Institutional Investor PLC (LON:ERM), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Euromoney Institutional Investor PLC has GBX 1450 highest and GBX 818 lowest target. GBX 1189’s average target is 5.69% above currents GBX 1125 stock price. Euromoney Institutional Investor PLC had 71 analyst reports since July 22, 2015 according to SRatingsIntel. On Friday, March 11 the stock rating was maintained by Numis Securities with “Add”. As per Monday, October 30, the company rating was maintained by Peel Hunt. The stock of Euromoney Institutional Investor PLC (LON:ERM) has “Hold” rating given on Monday, December 12 by Canaccord Genuity. The firm earned “Buy” rating on Thursday, September 28 by Peel Hunt. The firm has “Hold” rating by N+1 Singer given on Monday, November 16. On Thursday, November 24 the stock rating was maintained by Canaccord Genuity with “Hold”. The stock of Euromoney Institutional Investor PLC (LON:ERM) earned “Add” rating by Investec on Wednesday, July 22. Numis Securities upgraded Euromoney Institutional Investor PLC (LON:ERM) rating on Thursday, September 28. Numis Securities has “Buy” rating and GBX 1450 target. The stock of Euromoney Institutional Investor PLC (LON:ERM) has “Add” rating given on Friday, July 21 by Numis Securities. The rating was maintained by Peel Hunt with “Add” on Thursday, February 11.

Investors sentiment increased to 0.93 in Q2 2017. Its up 0.02, from 0.91 in 2017Q1. It is positive, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Victory Capital Management holds 280,370 shares. 494 were reported by Motco. Gateway Advisers Ltd invested in 0.52% or 826,704 shares. Integral Derivatives Limited Liability reported 53,304 shares. Bridgeway Mngmt stated it has 0.27% in Gilead Sciences, Inc. (NASDAQ:GILD). Mason Street Advsrs Limited Company owns 181,359 shares. Nelson Van Denburg And Campbell Wealth Management Gp Limited has invested 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD). Asset Mgmt One has invested 0.37% in Gilead Sciences, Inc. (NASDAQ:GILD). Burt Wealth Advsr stated it has 2,669 shares or 0.13% of all its holdings. Cutter Brokerage holds 0.61% or 21,895 shares in its portfolio. Rock Point Advsr Ltd Co invested in 4.12% or 123,777 shares. Hirtle Callaghan And Ltd Limited Liability Company holds 0% in Gilead Sciences, Inc. (NASDAQ:GILD) or 404 shares. 229,542 were accumulated by Atwood And Palmer. Waters Parkerson And Ltd invested in 0.03% or 4,210 shares. Westwood Inc reported 399 shares.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 EPS, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 11.28 P/E if the $1.67 EPS becomes a reality. After $2.23 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.12’s average target is 28.91% above currents $75.34 stock price. Gilead Sciences had 107 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 6. Jefferies maintained the stock with “Buy” rating in Monday, June 12 report. The stock has “Buy” rating by William Blair on Wednesday, June 14. The firm has “Buy” rating given on Tuesday, July 25 by Mizuho. The firm has “Outperform” rating by Credit Suisse given on Wednesday, February 3. Citigroup initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, February 25 with “Buy” rating. The company was upgraded on Tuesday, September 6 by Jefferies. Jefferies maintained the shares of GILD in report on Tuesday, October 25 with “Buy” rating. The firm has “Buy” rating given on Thursday, August 31 by Argus Research. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Overweight” rating given on Wednesday, February 3 by Piper Jaffray.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *